Introduction {#sec1-0300060520919238}
============

Osteomyelitis is a bone infection that can arise from contiguous spread, penetrating injury or hematogenous seeding.^[@bibr1-0300060520919238]^ The disease frequently becomes a chronic infection after the acute stage owing to inadequate treatment or relapse.^[@bibr2-0300060520919238]^ Chronic osteomyelitis (COM) can last for weeks, months, years or even be permanent, and involves pathological processes that induce intense inflammation in the foci because of the formation of abscesses, bone debris and sinus tracts.^[@bibr3-0300060520919238]^ Patients with COM are usually male and most are older.^[@bibr4-0300060520919238],[@bibr5-0300060520919238]^ COM can lead to chronic systemic inflammation, which is associated with multisystem disorders, including coronary artery disease, stroke, and head and neck cancer.^[@bibr6-0300060520919238][@bibr7-0300060520919238]--[@bibr8-0300060520919238]^

Suicide attempt is defined as an intentional act of taking one's life by engaging in self-directed injurious behaviors.^[@bibr9-0300060520919238],[@bibr10-0300060520919238]^ Suicide is the 10th leading cause of death in the United States, and its incidence has grown over the past 15 years.^[@bibr11-0300060520919238]^ The World Health Organization has predicted that there will be almost 1 million suicide deaths by 2030, contributing to a projected 1.4% of all deaths worldwide.^[@bibr9-0300060520919238]^ A previous study has suggested a correlation between neuroinflammation, as assessed by microglia activity in the brain, and suicidal ideation.^[@bibr12-0300060520919238]^ In one prospective study, subjects with higher levels of serum C-reactive protein had a higher risk of suicide death after 9 years of follow-up.^[@bibr13-0300060520919238]^

Despite that COM can lead to chronic systemic inflammation, and systemic inflammation is associated with suicide tendency, no studies have examined the correlation between COM and suicide tendency. We thus performed a nationwide population-based study to determine the epidemiology of health care service use for suicide, including suicide attempt or suicide death, among COM patients. Suicide deaths/attempts are here expressed as fatal/non-fatal suicide throughout.

Materials and methods {#sec2-0300060520919238}
=====================

Data source {#sec3-0300060520919238}
-----------

Since 1995, the Taiwanese government has been developing the National Health Insurance Research Database (NHIRD). The database includes data for more than 99% of Taiwanese citizens and their medical records. The Longitudinal Health Insurance Database (LHID), which randomly selects 1 million subjects from the NHIRD, was used in this study. To protect the privacy of the beneficiaries, original identification numbers were encrypted before the data were released. The ICD-9-CM (International Classification of Diseases, 9th Revision, Clinical Modification) system was used for disease coding in the NHIRD and LHID.

The research ethics committee of China Medical University Hospital in Taiwan approved the study (CMUH-104-REC2-115-R3).^[@bibr14-0300060520919238]^ The committee confirmed that informed consent was not required, as the identity of the participants could not be determined. All the data analyzed were encrypted in terms of participant identity when released from the NHIRD.

Study population {#sec4-0300060520919238}
----------------

We used a population-based cohort study to determine the epidemiology of fatal/non-fatal suicide, including suicide attempt or suicide death, among COM patients. Subjects with at least two outpatient visits or one course of inpatient care (or both) diagnosed with COM (ICD-9-CM: 730.1--730.9, 909.3) from January 2000 to December 2012 were recruited into a COM cohort. The index date was defined as the date when the COM diagnosis was initially coded. The control/COM subject ratio was approximately 4:1 matched by age, sex, a coding of major depression and index year (COM patients). Subjects with a history of at least two outpatient visits or one course of inpatient care with a coding of major depression (ICD-9-CM: 296.2, 296.3, 296.82, 300.4, 309.0, 309.1, 309.28, 311) before the index date were diagnosed with major depression. Subjects with previous suicide coding (ICD-9-CM: E950--E959) and subjects \<20 years old before the index date were excluded. All subjects were followed up from the index date until the date of initial suicide coding (ICD-9-CM: E950--E959), until they were withdrawn from the database or until 31 December 2013. Suicide death, or fatal suicide, was defined as death within 30 days of the suicide-coded (ICD-9-CM: E950--E959) date. Suicide attempt, or non-fatal suicide, was defined as the absence of death within 30 days of suicide coding (ICD-9-CM: E950--E959). Fatal/non-fatal suicides, including suicide attempts or suicide deaths, were defined as events in a Cox regression model. The mean (±standard deviation) follow-up period was 6.3 ± 4.1 years.

The baseline comorbidities analyzed in our model were hypertension (ICD-9-CM: 401--405), diabetes (ICD-9-CM: 250), epilepsy (ICD-9-CM: 345), ischemic heart disease (ICD-9-CM: 410--414), chronic obstructive pulmonary disease (ICD-9-CM: 491, 492, 493, 496), stroke (ICD-9-CM: 430--438), liver cirrhosis (ICD-9-CM: 571.2, 571.5), osteoporosis (ICD-9-CM: 733), end-stage renal disease (ICD-9-CM: 585), bipolar disorders (ICD-9-CM: 296.0, 296.1, 296.4, 296.5, 296.6, 296.7, 296.8, 296.80 and 296.89) and schizophrenia (ICD-9-CM: 295 and A211). Subjects with at least two outpatient visits or one course of inpatient care under the aforementioned coding before the index date were diagnosed with the specific comorbidity.

Statistical analysis {#sec5-0300060520919238}
--------------------

We described the sex, age group, level of urbanization and comorbidities in both cohorts using number of subjects and percentages. The mean age was expressed as mean ± standard deviation. Chi-square tests and t-tests were used to estimate differences in categorical and continuous variables between the two cohorts. To estimate the risk of fatal/non-fatal suicide in the COM cohort relative to the comparison cohort, hazard ratios (HR) and adjusted hazard ratios (aHR) were calculated using crude and adjusted Cox proportional hazard models, respectively. The incidence density of fatal/non-fatal suicide was expressed as event number per 100,000 person-years. The Kaplan--Meier method was used to determine the cumulative incidence of fatal/non-fatal suicide, and the log-rank test was used to determine the significance of between-group differences. SAS 9.4 software (SAS Institute Inc., Cary, NC, USA) was used for data analysis and R software ([www.r-project.org](http://www.r-project.org)) was used to plot the incidence curves.^[@bibr14-0300060520919238]^

Results {#sec6-0300060520919238}
=======

There were 5,762 patients in the COM cohort and 23,039 subjects in the control cohort ([Table 1](#table1-0300060520919238){ref-type="table"}). The study design and the flow diagram of the recruitment process are shown in [Figure 1](#fig1-0300060520919238){ref-type="fig"}. Sex and age were homogenous between the two groups. The urbanization level was substantially different between the two cohorts, and COM patients had significantly more baseline comorbidities (all *P* values \< 0.001) except depression and bipolar disorder ([Table 1](#table1-0300060520919238){ref-type="table"}).

###### 

Demographic characteristics and baseline comorbidities of the chronic osteomyelitis and control cohorts.

![](10.1177_0300060520919238-table1)

  Characteristics                                                             Total    Chronic osteomyelitis   *P*-value       
  --------------------------------------------------------------------------- -------- ----------------------- --------------- ---------
  Sex                                                                                                                          0.99
   Female                                                                     12,244   9,795 (42.5)            2,449 (42.5)    
   Male                                                                       16,557   13,244 (57.5)           3,313 (57.5)    
  Age (years)                                                                                                                  1.00
   \<45                                                                       6,675    5,340 (23.2)            1,335 (23.2)    
   45--64                                                                     11,295   9,036 (39.2)            2,259 (39.2)    
   ≥65                                                                        10,831   8,663 (37.6)            2,168 (37.6)    
  Mean ± SD^a^                                                                         57.97 ± 16.85           58.05 ± 16.88   
  Urbanization level^[†](#table-fn3-0300060520919238){ref-type="table-fn"}^                                                    \<0.001
   1 (highest)                                                                8,157    6,854 (29.8)            1,303 (22.6)    
   2                                                                          8,337    6,668 (29)              1,669 (29)      
   3                                                                          4,789    3,822 (16.6)            967 (16.8)      
   4                                                                          7,479    5,664 (24.6)            1,815 (31.5)    
  Baseline comorbidity                                                                                                         
   Depression                                                                 2,814    2,250 (9.8)             564 (9.8)       0.96
   Hypertension                                                               12,849   9,795 (42.5)            3,054 (53)      \<0.001
   Diabetes                                                                   6,827    4,807 (20.9)            2,020 (35.1)    \<0.001
   Epilepsy                                                                   458      303 (1.3)               155 (2.7)       \<0.001
   IHD                                                                        7,473    5,636 (24.5)            1,837 (31.9)    \<0.001
   COPD                                                                       7,101    5,439 (23.6)            1,662 (28.8)    \<0.001
   Stroke                                                                     5,533    4,066 (17.6)            1,467 (25.5)    \<0.001
   Liver cirrhosis                                                            715      431 (1.9)               284 (4.9)       \<0.001
   Osteoporosis                                                               4,130    2,762 (12)              1,368 (23.7)    \<0.001
   ESRD                                                                       328      141 (0.6)               187 (3.2)       \<0.001
   Bipolar disorder                                                           225      179 (0.8)               46 (0.8)        0.87
   Schizophrenia                                                              317      225 (1.0)               92 (1.6)        \<0.001

IHD: ischemic heart disease; COPD: chronic obstructive pulmonary disease; ESRD: end-stage renal disease; SD: standard deviation.

Chi-square test, ^a^t-test. Data are N (%) unless otherwise stated.

^†^Urbanization level was obtained by classifying the population density of the residential area in terms of four levels (level 1 = highest urbanization; level 4 = lowest urbanization).

![Flow diagram of the recruitment process.\
LHID: Longitudinal Health Insurance Database.](10.1177_0300060520919238-fig1){#fig1-0300060520919238}

The incidence of fatal/non-fatal suicide in the COM group and the control group was 55.30 and 24.68 per 100,000 person-years, respectively. COM patients had 1.93 times the risk of fatal/non-fatal suicide (aHR = 1.93, 95% confidence interval \[CI\]: 1.11--3.36; *P* = 0.02) than control subjects ([Table 2](#table2-0300060520919238){ref-type="table"}). Considering death as the competing event for fatal/non-fatal suicide, COM patients had 1.76 times the risk of fatal/non-fatal suicide (aHR = 1.76, 95% CI: 1.03--3.01; *P* = 0.04) than control subjects in the competing risks regression model ([Table 3](#table3-0300060520919238){ref-type="table"}). The cumulative incidence of fatal/non-fatal suicide was higher in the COM group than in the control group (*P* = 0.003 for log-rank test) ([Figure 2](#fig2-0300060520919238){ref-type="fig"}). Other risk factors for fatal/non-fatal suicide were urbanization level, depression (aHR =3.82, 95% CI: 2.06--7.07; *P* \< 0.001), IHD (aHR = 2.25, 95% CI: 1.17--4.34; *P* =0.02), liver cirrhosis (aHR = 3.12, 95% CI: 1.19--8.16; *P* = 0.02) and bipolar disorder (aHR = 3.29, 95% CI: 1.09--9.94; *P* = 0.03) ([Table 2](#table2-0300060520919238){ref-type="table"}). The effect of COM on the increased risk of fatal/non-fatal suicide was more prominent among diabetic patients (aHR = 3.79, 95% CI: 1.42--10.16; *P* \< 0.01) ([Table 4](#table4-0300060520919238){ref-type="table"}).

###### 

Incidence of fatal/non-fatal suicide stratified by presence of chronic osteomyelitis, sex, age, urbanization and baseline comorbidities.

![](10.1177_0300060520919238-table2)

  Characteristics           E    PY        IR       Crude                 Adjusted^[\#](#table-fn5-0300060520919238){ref-type="table-fn"}^                        
  ------------------------- ---- --------- -------- --------------------- ------------------------------------------------------------------ -------------------- ---------
  COM                                                                                                                                                             
   No                       40   16,2074   24.68    Ref.                                                                                     Ref.                 
   Yes                      20   3,6169    55.30    2.23 (1.30--3.82)     0.003                                                              1.93 (1.11--3.36)    0.02
  Sex                                                                                                                                                             
   Female                   25   8,5508    29.24    Ref.                                                                                     Ref.                 
   Male                     35   11,2735   31.05    1.06 (0.63--1.76)     0.84                                                               1.09 (0.64--1.87)    0.75
  Age at baseline (years)                                                                                                                                         
   \<45                     18   53,947    33.37    Ref.                                                                                     Ref.                 
   45--64                   21   81,884    25.65    0.76 (0.40--1.42)     0.39                                                               0.61 (0.31--1.20)    0.15
   ≥65                      21   62,412    33.65    0.96 (0.51--1.81)     0.91                                                               0.57 (0.25--1.30)    0.18
  Urbanization                                                                                                                                                    
   1 (highest)              11   56,261    19.55    Ref.                                                                                     Ref.                 
   2                        12   57,941    20.71    1.06 (0.47--2.40)     0.89                                                               1.01 (0.44--2.29)    0.98
   3                        10   33,526    29.83    1.53 (0.65--3.60)     0.33                                                               1.48 (0.63--3.50)    0.37
   4                        27   50,275    53.70    2.74 (1.36--5.52)     0.005                                                              2.47 (1.22--5.03)    0.01
  Comorbidities                                                                                                                                                   
   Depression               19   15,431    123.13   5.29 (3.06--9.13)     \<0.001                                                            3.82 (2.06--7.07)    \<0.001
   Hypertension             27   77,013    35.06    1.25 (0.75--2.08)     0.40                                                               0.66 (0.33--1.31)    0.23
   Diabetes                 18   38,911    46.26    1.70 (0.98--2.96)     0.06                                                               1.21 (0.64--2.28)    0.56
   Epilepsy                 2    2,417     82.75    2.69 (0.66--11.04)    0.17                                                               0.97 (0.22--4.24)    0.97
   IHD                      25   43,754    57.14    2.46 (1.47--4.11)     \<0.001                                                            2.25 (1.17--4.34)    0.02
   COPD                     19   40,268    47.18    1.74 (1.01--3.01)     0.05                                                               1.28 (0.69--2.35)    0.43
   Stroke                   18   30,398    59.21    2.30 (1.32--3.99)     0.003                                                              1.52 (0.78--2.99)    0.22
   Liver cirrhosis          5    3,239     154.39   5.24 (2.09--13.13)    \<0.001                                                            3.12 (1.19--8.16)    0.02
   Osteoporosis             8    23,789    33.63    1.09 (0.52--2.30)     0.82                                                               0.64 (0.29--1.44)    0.28
   ESRD                     1              92.60    2.91 (0.40--21.05)    0.29                                                               1.62 (0.21--12.22)   0.64
   Bipolar disorder         4    1,256     318.46   10.82 (3.92--29.84)   \<0.001                                                            3.29 (1.09--9.94)    0.03
   Schizophrenia            2    1,836     108.94   3.59 (0.88--14.69)    0.08                                                               1.20 (0.27--5.22)    0.81

E: number of suicide attempts or suicide deaths; PY: person-years; IR: incidence rate per 100,000 person-years; HR: hazard ratio; CI: confidence interval; IHD: ischemic heart disease; COPD: chronic obstructive pulmonary disease; ESRD: end-stage renal disease; COM: chronic osteomyelitis.

^\#^Adjusted for sex, age, urbanization and all comorbidities.

###### 

Subhazard ratios for fatal/non-fatal suicide estimated using a competing risks regression model.

![](10.1177_0300060520919238-table3)

  Variable                   Chronic osteomyelitis   *P*-value           
  -------------------------- ----------------------- ------------------- -------------------------------------------------------------
  Suicide                                                                
  Crude SHR (95% CI)         1.00 (Ref.)             2.14 (1.25--3.64)   0.005\*\*
  Adjusted SHR^†^ (95% CI)   1.00 (Ref.)             1.76 (1.03--3.01)   0.040[\*](#table-fn8-0300060520919238){ref-type="table-fn"}

Crude SHR: relative subhazard ratio; CI: confidence interval.

Adjusted SHR^†^: multivariable analysis including all factors in the univariable Cox model.

\**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001.

![Incidence of suicide attempts and suicide deaths among chronic osteomyelitis (COM) and control cohorts. The dashed line indicates the COM cohort and the solid line indicates the matched control cohort. The log-rank test was used to assess the significance of the difference between the curves (*P* = 0.003).](10.1177_0300060520919238-fig2){#fig2-0300060520919238}

###### 

Crude and adjusted hazard ratios for fatal/non-fatal suicide stratified by sex, age, urbanization and baseline comorbidities.

![](10.1177_0300060520919238-table4)

  Variables           Control group   COM group   COM group vs. control group                                                                                                      
  ------------------- --------------- ----------- ----------------------------- ---- -------- -------- --------------------------------------------------------------------------- -----------------------------------------------------------------------------
  Overall             40              162,074     24.68                         20   36,169   55.30    2.23 (1.30--3.82)\*\*                                                       1.93 (1.11--3.36)[\*](#table-fn11-0300060520919238){ref-type="table-fn"}
   Suicide attempt    35              162,074     21.60                         16   36,169   44.24    2.04 (1.13--3.68)[\*](#table-fn11-0300060520919238){ref-type="table-fn"}    1.58 (0.86--2.92)
   Suicide death      5               162,074     3.09                          4    36,169   11.06    3.62 (0.97--13.48)                                                          3.72 (0.95--14.58)
  Sex                                                                                                                                                                              
   Female             17              69,528      24.45                         8    15,980   50.06    2.05 (0.88--4.75)                                                           1.56 (0.66--3.73)
   Male               23              92,546      24.85                         12   20,189   59.44    2.37 (1.18--4.76)[\*](#table-fn11-0300060520919238){ref-type="table-fn"}    2.02 (0.98--4.18)
  Age (years)                                                                                                                                                                      
   \<45               12              43,484      27.60                         6    10,463   57.34    2.07 (0.78--5.52)                                                           1.60 (0.54--4.69)
   45--64             13              66,896      19.43                         8    14,988   53.38    2.73 (1.13--6.6)[\*](#table-fn11-0300060520919238){ref-type="table-fn"}     2.04 (0.79--5.21)
   ≥65                15              51,694      29.02                         6    10,718   55.98    1.92 (0.75--4.96)                                                           1.88 (0.72--4.92)
  Urbanization                                                                                                                                                                     
   1 (highest)        7               48,482      14.44                         4    7,779    51.42    3.51 (1.03--12.01)[\*](#table-fn11-0300060520919238){ref-type="table-fn"}   2.47 (0.70--8.71)
   2                  6               47,283      12.69                         6    10,657   56.30    4.39 (1.42--13.62)[\*](#table-fn11-0300060520919238){ref-type="table-fn"}   3.07 (0.87--10.74)
   3                  6               27,092      22.15                         4    6,433    62.18    2.82 (0.8--10.00)                                                           2.69 (0.69--10.54)
   4                  21              39,003      53.84                         6    11,272   53.23    0.99 (0.40--2.45)                                                           1.02 (0.41--2.59)
  Comorbidities                                                                                                                                                                    
   Depression         13              12,677      102.54                        6    2,754    217.89   2.13 (0.81--5.61)                                                           2.25 (0.86--6.15)
   Hypertension       17              60,812      27.95                         10   16,201   61.72    2.21 (1.01--4.82)[\*](#table-fn11-0300060520919238){ref-type="table-fn"}    1.89 (0.84--4.26)
   Diabetes           7               28,793      24.31                         11   10,118   108.71   4.31 (1.67--11.11)\*\*                                                      3.79 (1.42--10.16)\*\*
   Epilepsy           1               17,03.3     58.71                         1    714      140.10   --                                                                          7.6 (0.14--422.92)
   IHD                19              34,444      55.16                         6    9,310    64.45    1.17 (0.47--2.92)                                                           1.11 (0.43--2.87)
   COPD               13              31,876      40.78                         6    8,391    71.50    1.73 (0.66--4.56)                                                           1.58 (0.57--4.38)
   Stroke             14              23,345      59.97                         4    7,054    56.71    0.95 (0.31--2.89)                                                           0.90 (0.29--2.84)
   Liver cirrhosis    1               21,04.8     47.51                         4    1,134    352.81   6.89 (0.77--61.69)                                                          17.46 (1.27--240.21)[\*](#table-fn11-0300060520919238){ref-type="table-fn"}
   Osteoporosis       4               16,270      24.58                         4    7,519    53.20    2.11 (0.53--8.44)                                                           1.14 (0.25--5.22)
   ESRD               0               569,27      0.00                          1    511      195.85   --                                                                          --
   Bipolar disorder   3               97,7.92     306.77                        1    278      359.56   1.28 (0.13--12.32)                                                          0.99 (0.04--24.16)
   Schizophrenia      2               13,23.1     151.17                        0    513      0.00     --                                                                          --

E: number of suicide attempts or suicide deaths; PY: person-years; IR: incidence rate per 100,000 person-years; HR: hazard ratio; CI: confidence interval; IHD: ischemic heart disease; COPD: chronic obstructive pulmonary disease; ESRD: end-stage renal disease; COM: chronic osteomyelitis.

^\#^Adjusted for sex, age, urbanization and all comorbidities in the Cox proportional hazards regression model.

\**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001.

Compared with the control cohort, we observed a severity-dependent risk of fatal/non-fatal suicide associated with COM after controlling for age, sex, urbanization level and medical comorbidities (outpatients only: aHR = 1.81, 95% CI: 1.02--3.22; outpatients and inpatients: aHR = 4.79; 95% CI: 1.08--21.34; *P* for trend = 0.0006) ([Table 5](#table5-0300060520919238){ref-type="table"}).

###### 

Incidence rate and adjusted hazard ratios for fatal/non-fatal suicide stratified by chronic osteomyelitis severity.

![](10.1177_0300060520919238-table5)

  COM severity                 Event   PY        IR       Adjusted HR (95% CI)
  ---------------------------- ------- --------- -------- ---------------------------------------------------------------------------
  Control group                40      162,074   24.68    Ref.
  Outpatients only             18      35,541    50.65    1.81 (1.02--3.22)[\*](#table-fn14-0300060520919238){ref-type="table-fn"}
  Outpatients and inpatients   2       628       318.32   4.79 (1.08--21.34)[\*](#table-fn14-0300060520919238){ref-type="table-fn"}
  *P* for trend                                           *P* = 0.0006

PY: person-years; IR: incidence rate per 100,000 person-years; HR: hazard ratio; CI: confidence interval; COM: chronic osteomyelitis.

Models adjusted by demographic factors and comorbidities.

\**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001.

Discussion {#sec7-0300060520919238}
==========

COM is a disease that can contribute to chronic systemic inflammation, and its fluctuating and relentless course can present substantial psychological burden to patients. Chronic systemic inflammation has been recently shown to be correlated with suicide tendency,^[@bibr9-0300060520919238]^ indicating that long-term illness is a potential proximal risk factor for suicide. It is therefore likely that COM patients have a greater suicide tendency. In this study, we demonstrated that COM patients had 1.93 times the risk of fatal/non-fatal suicide than control subjects. Considering death as the competing event, COM patients had 1.76 times the risk of fatal/non-fatal suicide than control subjects using a competing risk regression model. The effect of COM on fatal/non-fatal suicide was more prominent among diabetic patients. We also showed that higher COM severity was associated with greater risk of fatal/non-fatal suicide. This is the first report of such a link, so these results merit attention.

Infections can induce systemic inflammation and subsequent neuroinflammatory processes, which may lead to the onset of suicide symptoms.^[@bibr9-0300060520919238]^ The prevalence of suicidal ideation and attempted suicide among human immunodeficiency virus patients is 31% and 32.7%, respectively.^[@bibr15-0300060520919238]^ Before medical treatment, 36% of chronic hepatitis C patients experience major depression and 18% have a moderate-to-severe suicide risk.^[@bibr16-0300060520919238]^ Latent Toxoplasma gondii infection has been recognized as a risk factor for suicide attempt.^[@bibr17-0300060520919238],[@bibr18-0300060520919238]^ Despite the known correlation between suicide tendency and the various infections mentioned above, no studies have examined the correlation between COM and suicide tendency. To our knowledge, this is the first study to demonstrate a correlation between COM and increased risk of fatal/non-fatal suicide. The incidence of fatal/non-fatal suicide, including suicide attempt or suicide death, was higher in the COM group than in the control group. The cumulative incidence of suicide attempt or suicide death was higher in the COM group than in the control group. We also demonstrated that among COM patients receiving both inpatient and outpatient care, the incidence of suicide attempt or suicide death was as high as 318.32 per 100,000 person-years. In other words, COM patients receiving both outpatient and inpatient care had 4.79 times the risk of fatal/non-fatal suicide (aHR = 4.79, 95% CI: 1.08--21.34) than control subjects. These results highlight the effect of COM on suicide occurrence.

There are some study limitations. The definition of diseases was based only upon ICD-9-CM coding, so the severity, frequency and duration of treatment for respective diseases could not be fully investigated. We could not obtain data for all suicide risk factors (e.g. family history) from the LHID database. Only data for subjects seeking medical services owing to suicide attempt or subsequent suicide death could be obtained from the LHID database, so subjects with suicidal ideation or suicide plans could not be identified. The relatively low incidence rate of coded suicide events meant that some subgroup analyses, such as the fatal or non-fatal comparison, may have been underpowered. Finally, we could only obtain 23,039 matching subjects from the LHID instead of 23,048.

Conclusions {#sec8-0300060520919238}
===========

These findings demonstrate that COM is a risk factor for fatal/non-fatal suicide, including suicide attempts and suicide death. The relative importance of COM as a risk factor for fatal/non-fatal suicide was greater among diabetic patients. These data indicate that COM is not merely a local musculoskeletal disease and its association with suicide tendency justifies preventive measures for suicide attempts or suicide deaths among COM patients.

Data availability {#sec9-0300060520919238}
=================

The data used to support the findings of this study are restricted by the research ethics committee of China Medical University Hospital in Taiwan to protect patient privacy. Data are available from the corresponding author (Shu-Jui Kuo) for researchers who meet the criteria for access to confidential data.

Declaration of conflicting interests {#sec10-0300060520919238}
====================================

The authors declare that there is no conflict of interest.

Funding {#sec11-0300060520919238}
=======

This study was supported by the Ministry of Health and Welfare, Taiwan (MOHW107-TDU-B-212-123004), China Medical University Hospital, the Academia Sinica Stroke Biosignature Project (BM10701010021), MOST Clinical Trial Consortium for Stroke (MOST 106-2321-B-039-005), the Tseng-Lien Lin Foundation (Taiwan), the Brain Disease Foundation (Taiwan), the Katsuzo and Kiyo Aoshima Memorial Funds, Japan, and grants CMRPG8B1301-CRRPG8B1303 and CRRPG8F0461-CRRPG8F0463 from Chang Gung Medical.

ORCID iDs
=========

Chieh-Cheng Hsu <https://orcid.org/0000-0002-8372-2599>

Shu-Jui Kuo <https://orcid.org/0000-0002-2992-4608>
